Abstract
The dysregulated expression of glycolysis-related genes (GRGs) is closely related to the occurrence of diverse tumors and regarded as a novel target of tumor therapy. However, the role of GRGs in colon cancer is unclear. We obtained 226 differential GRGs (DE-GRGs) from The Cancer Genome Atlas (TCGA) database. Cox regression analysis was used to construct a DE-GRG prognostic model, including P4HA1, PMM2, PGM2, PPARGC1A, PPP2CB, STC2, ENO3, and CHPF2. The model could accurately predict the overall survival rate of TCGA and GSE17536 patient cohorts. The risk score of the model was closely related to a variety of clinical traits and was an independent risk factor for prognosis. Enrichment analysis revealed the activation of a variety of glycolysis metabolism and immune-related signaling pathways in the high-risk group. High-risk patients displayed low expression of CD4+ memory resting T cells and resting dendritic cells and high expression of macrophages M0 compared with the expression levels in the low-risk patients. Furthermore, patients in the high-risk group had a higher tumor mutation load and tumor stem cell index and were less sensitive to a variety of chemotherapeutic drugs. Quantitative reverse transcription polymerase chain reaction and immunohistochemistry analyses validated the expression of eight GRGs in 43 paired clinical samples. This is the first multi-omics study on the GRGs of colon cancer. The establishment of the risk model may benefit the prognosis and drug treatment of patients.
Highlights
Colon cancer is the most prevalent gastrointestinal malignancy
The findings indicate the utility of the model as a powerful tool for the prognosis and treatment of colon cancer
As increased aerobic glycolysis activity plays a significant role in cancer development, we explored the prognostic importance of glycolysis-related genes (GRGs) in colon cancer (Figure 1)
Summary
Colon cancer is the most prevalent gastrointestinal malignancy. It is the third-ranked malignancyrelated death globally (Arnold et al, 2020). Colon cancer is a multifactorial disease, and its causes could. GRGs in Colon Cancer include genetic predisposition, lifestyle changes, and diet (Pilleron et al, 2019; Vuik et al, 2019). Despite recent advancements in medicine, diagnostics tools, and surgical techniques, the annual incidence and mortality rates of colon cancer continue to increase appreciably, and the 5-year survival rate is less than 15% (Kalyan et al, 2018; Ladabaum et al, 2020). It is crucial to discover new biomarkers and therapeutic drug targets for the rapid diagnosis and treatment of colon cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
